肺癌多药耐药基因表达与化疗耐药的临床研究  

Clinical study on multidrug-resisitant gene and resistance to chemotherapy in pulmonary cancer patients.

作　　者：周卫平[1] 刘海[1] 汤鹏[1] 梁茱[1] 

机构地区：[1]海南省人民医院肿瘤外科,海南海口570311

出　　处：《中国热带医学》2004年第5期701-702,共2页China Tropical Medicine

摘　　要：目的　研究P -糖蛋白在肺癌中的表达及其与肺癌化疗耐药之间的关系。　方法　对 3 3例原发性肺癌病例的癌组织病理切片进行免疫组织化学检测 ,了解P -糖蛋白在肺癌组织中的阳性表达率。　结果　P -糖蛋白在肺腺癌、鳞癌及小细胞癌中的阳性表达率分别是 62 5 %、14 2 %和 0 :在不能手术切除而进行全身化疗的 12例患者中 ,P -糖蛋白表达阴性的8例患者 ,有 6例PR或CR ;而P -糖蛋白表达阳性的 4例 ,全部无效或进展。　结论　P -糖蛋白阳性表达率在肺腺癌中最高 ,鳞癌次之 ,小细胞肺癌最低 ;P -糖蛋白是导致肺癌耐药的主要原因。Objective To investigate the expression of p-glucoprotein in lung carcinoma and the relationship between lung carcinoma and drug resistance. Methods immunocytochemical detection of pathological sections of 33 primary pulmonary carcinoma patients' tissue was carried out for understanding the positive expression of p-glucoprotein. Results The positive rates of p-glucoprotein expressed pulmonary adenocarcinoma, squamous and small cell carcinoma were 62.5%,14.2% and 0, respectively. Negative expression of p-glucoprotein was observed in 8 out of the 12 patients not suitable for operational treatment and undergone general chemotherapy. Of the 8 patients 6 were complete or partial relieved. The treatment failed or worsen in other 4 patients positive expression of p-glucoprotein. Conclusion P-glucoprotein is the main cause resulting in pulmonary carcinoma and its expression rate is the highest in adenocarcinoma, next in squamous carcinoma and lowest in small cell carcinoma.

关 键 词：P-糖蛋白 肺癌 阳性表达率 化疗耐药 肺腺癌 多药耐药基因 鳞癌 结论 目的 方法 

分 类 号：R734.2[医药卫生—肿瘤] R737[医药卫生—临床医学]